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ABSTRACT Brain insulin resistance is a key pathological feature contributing to
obesity, diabetes, and neurodegenerative disorders, including Alzheimer’s disease (AD).
Besides the classic transcriptional mechanism mediated by hormones, posttranscrip-
tional regulation has recently been shown to regulate a number of signaling path-
ways that could lead to metabolic diseases. Here, we show that microRNA 7 (miR-7),
an abundant microRNA in the brain, targets insulin receptor (INSR), insulin receptor
substrate 2 (IRS-2), and insulin-degrading enzyme (IDE), key regulators of insulin ho-
meostatic functions in the central nervous system (CNS) and the pathology of AD. In
this study, we found that insulin and liver X receptor (LXR) activators promote the
expression of the intronic miR-7-1 in vitro and in vivo, along with its host heteroge-
neous nuclear ribonucleoprotein K (HNRNPK) gene, encoding an RNA binding pro-
tein (RBP) that is involved in insulin action at the posttranscriptional level. Our data
show that miR-7 expression is altered in the brains of diet-induced obese mice.
Moreover, we found that the levels of miR-7 are also elevated in brains of AD pa-
tients; this inversely correlates with the expression of its target genes IRS-2 and IDE.
Furthermore, overexpression of miR-7 increased the levels of extracellular A in neu-
ronal cells and impaired the clearance of extracellular A by microglial cells. Taken
together, these results represent a novel branch of insulin action through the
HNRNPK–miR-7 axis and highlight the possible implication of these posttranscrip-
tional regulators in a range of diseases underlying metabolic dysregulation in the
brain, from diabetes to Alzheimer’s disease.
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Although the brain was once considered an insulin-insensitive organ, it is nowestablished that insulin actions regulate important functions in the central nervous
system (CNS), including synaptic plasticity, learning and memory, and neuroprotection.
Insulin receptor (INSR), insulin-like growth factor receptor (IGFR), and their signaling
partners, such as insulin receptor substrate 1 (IRS-1) and IRS-2, are distributed through-
out the brain and regulate processes such as neurogenesis, cell growth, and synaptic
maintenance, as well as amyloid- peptide (A) degradation. Importantly, impairment
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of insulin signaling in the brain is associated with the development of a number of
pathologies, including diabetes and Alzheimer’s disease (AD). The development of
diabetes and AD has been found to share many pathophysiological features, including
insulin resistance (IR), impaired glucose metabolism, and cognitive decline. Individuals
with diabetes have a 1.5- to 2.0-fold-higher risk of developing AD than individuals
without diabetes (1). Insulin can exert neuroprotective effects by preventing Tau
hyperphosphorylation and promoting the extracellular degradation of A through the
regulation of insulin-degrading enzyme (IDE), which represents a key molecular link
between AD and diabetes (2). Furthermore, intranasal administration of insulin has
been shown to improve cognitive decline in AD patients (3). As such, understanding the
biological mechanisms that link the development of diabetes with AD is essential for
the development of future intervention and/or prevention strategies.
MicroRNAs (miRNAs) are small (18 to 25 nucleotides [nt]), evolutionarily conserved,
noncoding RNAs that have an important function in gene regulation, acting predom-
inantly at the posttranscriptional level. By binding to the 3= untranslated regions (UTRs)
of target mRNAs, miRNAs repress translation or induce mRNA degradation (4, 5). A
growing number of studies from our group and others have demonstrated a critical role
for miRNAs in regulating lipid and glucose homeostasis, including miRNA 33 (miR-33),
miR-758, miR-144, and let-7, etc., and their impact on metabolic diseases (6–9). Of note,
the expression of many of these miRNAs is altered in aberrant metabolic states such as
diabetes as well as in AD, important pathologies where dysregulation of lipid and
glucose metabolism represents a common feature (10, 11). However, the role of
miRNAs in regulating insulin sensitivity in the brain in the context of AD remains
unexplored. Therefore, miRNAs may represent novel candidates to link AD and insulin
resistance in the CNS at the molecular level.
miR-7 is an evolutionarily highly conserved miRNA that is considered a prototypical
neuroendocrine miRNA, being highly expressed in neuroendocrine organs such as the
pancreas and brain (12). In humans, the miR-7 family consists of three members
(miR-7-1, miR-7-2, and miR-7-3) localized on human chromosomes 9, 15, and 19,
respectively. miR-7 has been shown to regulate important aspects of pancreatic biology
and functions, including cell differentiation and insulin production (12, 13), whereas its
role in the brain remains incomplete. Nevertheless, miR-7 expression seems to be
highly regulated in the brain by several other posttranscriptional regulators, such as
RNA binding proteins (RBPs) (14) and miRNA sponges (15), suggesting its important
role in the CNS. We have identified miR-7 as a potential candidate involved in the
regulation of brain insulin resistance and AD pathology. Using bioinformatic prediction
algorithms and gene ontology (GO) enrichment analysis, we found that potential miR-7
targets are enriched in gene clusters involved in insulin signaling and related pathways
(INSR, IRS-1, phosphatidylinositol 3-kinase [PI3K], and IGF1R) and AD (most notably IDE).
miR-7-1 is an intronic miRNA located in HNRNPK, an RBP that was recently shown to be
involved in insulin actions at the posttranscriptional level (16). Furthermore, our results
show that miR-7 represses the expression of INSR, IRS-2, and IDE, among other
important members of the insulin signaling pathway, in mouse and human neuronal
cells. Moreover, we have also found that miR-7 is regulated by insulin and liver X
receptor (LXR) both in vitro and in vivo, effects that are likely mediated through
SREBP1c. Also, we found that miR-7 levels are aberrant in the brains of obese mice and
in susceptible brain areas of AD patients, which inversely correlate with the expression
of insulin-signaling genes and genes involved in A metabolism. Finally, our data show
that miR-7 can regulate A levels in vitro in neuronal cells. Overall, these data suggest
that miR-7 may regulate insulin signaling and A levels in the brain during the
progression of AD.
RESULTS
miR-7 is highly abundant in the brain and targets key elements of the insulin
signaling pathway and Alzheimer’s disease. The miR-7 family is a highly conserved
family of miRNAs consisting of three members, miR-7-1, miR-7-2, and miR-7-3, in
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humans, corresponding to miR-7a-1, miR-7a-2, and miR-7b in mice (Fig. 1A). Both
human and mouse miR-7 precursors give rise to identical mature forms (Fig. 1B),
indicating their conservation (Fig. 1C). However, their distinct genomic locations sug-
gest possible differential functions and/or regulation. Intriguingly, miR-7-1 and its
mouse counterpart miR-7a-1 are encoded within introns 16 and 17 of the human and
mouse HNRNPK genes, respectively (Fig. 1A). Analysis of precursors by quantitative
real-time PCR (qRT-PCR) in mouse tissues shows that miR-7a-1 is abundantly expressed
in the brain and in the liver, while precursors of miR-7a-2 and miR-7b are highly
expressed in the brain compared with other organs (Fig. 1D). Analysis of the mature
form indicates that the miR-7 expression level is relatively higher in brain than in other
organs (Fig. 1D). Further analysis by Northern blotting of different mouse brain tissues
FIG 1 miR-7 genomic locations, mouse tissue expression, and conservation of precursor and mature miR-7 among species. (A) Schematic representation of the
genomic locations of miR-7 family members in human and mouse. Human miR-7-1 and murine miR-7a-1 are located in introns 16 and 17 of the HNRNPK gene,
respectively. miR-7-2 and miR-7-3 are located in intergenic regions of human chromosomes 15 and 19. Murine miR-7 genes and their chromosome locations
are shown in gray. (B) Sequence alignment between human miR-7 family members. Seed sequences are indicated in boxes. Blue indicates the mature 5p and
3p sequences. (C) Gene expression analyses (qRT-PCR) of precursors and mature miR-7-1-5p in different mouse tissues normalized to snoRD68. Data are
expressed relative to the amount of miR-7-5p transcripts expressed in the heart. Results are means  SEM from three independent experiments. (D)
Representative Northern blot analysis of miR-7-5p in different brain tissues showing an enrichment in mouse hypothalamus. 5S rRNA was used as a loading
control. (E) Sequence alignment of the stem-loop and mature miR-7 among species. WAT, white adipose tissue; hsa, Homo sapiens (human); ptr, Pan troglodytes
(chimpanzee); mml,Macaca mulatta (rhesus macaque); str, Stronglyloide ratti; mmu,Mus musculus (mouse); rno, Rattus norvegicus (rat); ocu, Oryctolagus cuniculus
(rabbit); ssa, Salmo salar (Atlantic salmon); gga, Gallus gallus (chicken); xtr, Xenopus tropicalis (western clawed frog).
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revealed that miR-7 is highly abundant in the hypothalamus (Fig. 1E). To determine
which molecular pathways would be affected by miR-7 in the brain, we performed
predicted target gene analysis using a combination of bioinformatic tools for miRNA
target predictions (TargetScan [http://www.targetscan.org], gene ontology [Panther
{http://www.pantherdb.org/}], and protein-protein interactions [String {http://string-db
.org/}]). We found that miR-7 is a strong candidate to regulate genes involved in
metabolism, where insulin and insulin/IGF pathways markedly showed a significant
enrichment among them (Fig. 2A and B). Common predicted targets within these two
overrepresented pathways, including the INSR, IGF1R, AKT, IRS-1, and IRS-2 genes, were
subjected to protein-protein interaction analysis, showing that miR-7 might play an
important role in controlling insulin signaling (Fig. 2C). The number, type, and conser-
vation of predicted sites for the common target genes from both pathways are shown
in Fig. 2D. Given the role of insulin in maintaining brain homeostasis and the correlation
FIG 2 Bioinformatic analysis of predicted miR-7 target genes. (A) Gene ontology analysis using Panther software showing enriched pathways for predicted miR-7
target genes. VEGF, vascular endothelial growth factor; PDGF, platelet-derived growth factor; MAPK, mitogen-activated protein kinase. (B) Panther overrepre-
sentation test showing fractional-difference analysis to determine statistically significant pathways. *, P 0.01; **, P 0.001 (observed versus expected).
Pathways with a P value of 0.001 are highlighted in red. (C) Protein-protein interaction analysis scheme of common predicted miR-7-5p selected target genes
from highlighted pathways using String 9.1 software. (D) Predicted human target genes of miR-7 involved in insulin signaling, showing the number and type
of binding sites and their conservation in mouse.
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between brain insulin resistance and AD, we further explored whether other potential
target genes involved in this pathology might be predicted targets for miR-7. Our
bioinformatic analysis indicated that miR-7 potentially targets a number of genes
involved in different aspects of A metabolism, including the IDE, ABCA1, APP, PSEN1,
and BACE1 genes (Fig. 3). To confirm the impact of miR-7 on the expression of the
above-mentioned targets, we transfected miR-7-5p oligonucleotides in mouse N2a
neuronal cells. As shown in Fig. 4A, the overexpression of miR-7 significantly decreased
IRS-2, AKT, IGF1R, and IDE mRNA levels. Conversely, inhibition of endogenous levels of
miR-7 using anti-miR-7 oligonucleotides increased INSR, IRS-1, IRS-2, AKT, IGF1R, and
IDE mRNA levels (Fig. 4B). Similar results were found at the protein level when we
assessed their expression by Western blotting (Fig. 4C). Similar effects were observed
with INSR, IRS-2, and IDE when we overexpressed miR-7 in human SHSY5Y neuronal
cells (data not shown). Next, we analyzed the direct effect of miR-7 on the 3= UTRs of
the key targets of insulin signaling and AD. To do this, we cloned the 3= UTRs of the
INSR, IRS-2, and IDE genes into a luciferase reporter plasmid and assessed their activity
after miR-7-5p overexpression (Fig. 4D to F). The conservation and type of predicted
miR-7 binding sites are shown in the right panels and point mutations are indicated in
the top panels of Fig. 4D and E. Our data show that miR-7 significantly repressed INSR,
IRS-2, and IDE 3=-UTR activities, and the mutation of the miR-7 target sites relieved the
repression of the INSR, IRS-2, and IDE 3= UTRs, which is consistent with its direct
interaction with the mRNAs studied.
miR-7 impairs insulin signaling in neuronal cells. Given that miR-7 regulates the
expression of key elements in the insulin signaling cascade at the posttranscriptional
level, we investigated the effects of miR-7 on downstream signaling upon insulin
stimulation in neuronal cells. To this end, we transfected N2a cells with a control mimic
FIG 3 Analysis of miR-7 targets involved in Alzheimer’s disease and the SREBP1 pathway. (A) Bioinformatic analysis of prominent miR-7 target genes involved
in Alzheimer’s disease using GeneMania. Blue lines indicate pathway correlation, green lines indicate genetic interaction, and purple lines indicate coexpression.
(B) Predicted human target genes of miR-7 involved in Alzheimer’s disease, showing the number of putative binding sites and conservation in mouse. (C) Human
target genes of miR-7 involved in the SREBP1 pathway, showing the number of predicted binding sites and conservation in mouse. Analyses in panels B and
C were performed using TargetScan 6.2.
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FIG 4 miR-7 regulates multiple genes involved in the insulin signaling pathway in neuronal cells. (A and B) qRT-PCR analysis of INSR, AKT, IRS-1,
IRS-2, IGF1R, and IDE mRNA expression levels in N2a cells transfected with a control mimic (CM) or an miR-7-5p mimic (miR-7) (A) or a control
inhibitor (CI) or an miR-7-5p inhibitor (Inh-miR-7) (B). Data are expressed as relative expression levels and correspond to the means  SEM from
three independent experiments performed in triplicate *, P 0.05 (significantly different from cells transfected with a CM [normalized to a value
of 1]). (C) Representative Western blots of predicted insulin pathway-related genes in N2a cells transfected with a CM or miR-7 (left) or a CI or
Inh-miR-7 (right). Heat shock protein 90 (HSP90) was used as a loading control. (D to F, top) Human INSR, IRS-2, and IDE 3=-UTR sequences
containing target sites for miR-7-5p. Underlined sequences indicate the miR-7 binding sites. Nucleotides highlighted in red indicate the point
mutations in the miR-7 binding sites. (Bottom) Luciferase reporter activity in COS-7 cells transfected with the CM or miR-7 mimic and the INSR,
IRS-2, and IDE 3= UTRs (wild type [WT]) or the constructs containing the indicated point mutations (PM). Data are expressed as relative luciferase
activities compared to the activity in control samples cotransfected with an equal concentration of the CM and correspond to the means  SEM
from three experiments performed in triplicate. *, P 0.05 (significantly different from cells cotransfected with CM and the WT or PM 3= UTR).
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(CM) and miR-7, and 48 h later, we treated them with insulin (100 nM) at different time
points. As expected, AKT and glycogen synthase kinase 3 (GSK3) were phosphory-
lated upon insulin treatment (Fig. 5A). Overexpression of miR-7 markedly reduced the
phosphorylation of these proteins at each time point (Fig. 5A). Quantification analysis
of the Western blots showed significant reductions in phosphorylated AKT (p-AKT)
levels at all time points after insulin stimulation as well as in p-GSK3 levels except at
time zero and 30 min after treatment (Fig. 5B). As expected, IDE and IRS-2 levels, used
as positive controls for miR-7 overexpression, were also significantly reduced. These
results suggest a possible role for miR-7 in promoting insulin resistance in neuronal
cells.
miR-7-1 is synchronously induced with its host HNRNPK gene upon insulin
stimulation and in vitro and in vivo. A number of examples in the literature indicate
that miRNAs are very often involved in either positive or negative regulatory feedback
loops to fine-tune biological processes or specific signaling pathways. MicroRNAs can
be regulated transcriptionally or at the posttranscriptional level, and intronic miRNAs
are often cotranscribed with their host gene. Interestingly, recent studies have shown
that the HRNRPK gene, where miR-7-1 is encoded, mediates insulin actions in mice (16).
Therefore, we decided to explore whether insulin could influence HNRNPK and miR-7
expression in neuronal cells. To do this, we treated N2a cells with 100 nM insulin for 1,
3, 6, 12, and 24 h and then analyzed the expression of HNRNPK and miR-7. Our results
showed that insulin increased HNRNPK mRNA and protein levels (Fig. 6A), and this
induction correlated with significant increases in the precursor and mature forms of
miR-7a-1 (Fig. 6B and C). These data suggest that both miR-7 and its host gene are
cotranscribed in response to insulin stimulation in mouse neuronal cells. To further
explore these results in an in vivo setting, we focused on the mouse hypothalamus, as
it represents a key neuroendocrine tissue responsive to insulin and metabolic changes
under fasting and feeding conditions and also expresses miR-7 abundantly. Next, we
performed a series of experiments where we compared the hypothalamic expression
levels of HNRNPK in mice starved for 16 h (low circulating insulin levels) and starved
FIG 5 miR-7 regulates insulin signaling in N2a cells. (A) Representative Western blot analysis of IRS-2, IDE, p-AKT, AKT, p-GSK3, and GSK3 in
N2a cells transfected with the CM or miR-7 and treated with 100 nM insulin (Ins) at the indicated time points. IRS-2 and IDE were used as positive
controls for the effect of miR-7 overexpression. HSP90 was used as a loading control. (B) Relative protein levels compared to HSP90 (IRS-2 and
IDE) and p-AKT/total AKT ratio and p-GSK3/total GSK3 ratio compared to HSP90. *, P 0.05 (significantly different from cells transfected with
the CM at each time point of insulin treatment). Data correspond to results from a representative experiment among three that gave similar
results. A.U., arbitrary units.
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mice that were further intraperitoneally (i.p.) injected with glucose (to promote insulin
secretion). Using this approach, we found that HNRNPK mRNA and protein levels of
HNRNPK were induced after 1 h of glucose injection, compared with those in the
hypothalamus of starved mice, consistent with its transcriptional regulation in response
to insulin in the brain (Fig. 6D). Our Northern blot analysis showed that miR-7 levels are
also upregulated in the hypothalamus under the same conditions (Fig. 6E). We next
assessed the hypothalamic expression of miR-7 in streptozotocin (STZ)-treated mice,
which mimics type 1 diabetes. Under these conditions, hypothalamic miR-7 levels were
no longer induced after glucose injection in the absence of circulating insulin in
STZ-treated mouse hypothalamus (Fig. 6F). Overall, these results indicate that both
HNRNPK and miR-7 are cotranscribed in vivo upon insulin stimulation in the brain.
miR-7-1 transcription is induced by SREBP1 in vitro and in vivo. Based on our
previous findings, we sought to explore the potential transcriptional signatures in the
promoter region of miR-7’s host gene that may explain its regulation by insulin.
Previous computational methods have identified several transcriptional start sites
(TSSs) in the promoter site of HNRNPK. These correlate with epigenetic signatures,
including CpG islands and H3K4Me3 histone marks, consistent with an open chromatin
FIG 6 Expression of miR-7/HNRNPK is regulated by insulin in vitro and in vivo. (A) qRT-PCR and Western blot analysis of HNRPK in N2a cells
stimulated with 100 nM insulin at the indicated time points. (B and C) qRT-PCR analysis of precursor miR-7a-1 and mature miR-7 in N2a cells
showing significant induction upon insulin stimulation. Data represent the means SEM of results from three experiments performed in triplicate.
*, P 0.05 (significantly different from cells treated with insulin at time zero). (D) qRT-PCR and Western blot analysis of HNRNPK in hypothalamus
from fasted mice after 1 (F/G 1h) and 3 h (F/G 3h) of i.p. injection with 20 g/kg of body weight of glucose (n 4 per group). (E) Northern blot
analysis of miR-7 in hypothalamus from mice treated as described above for panel D (n 4 per group). 5S rRNA was used as a loading control.
Relative expression of miR-7/5S is expressed as a fold change compared to hypothalamus from fasted mice. (F, left) Northern blot analysis of miR-7
in hypothalamus from STZ-diabetic mice under fasting conditions after 0 and 1 h of i.p. injection with 20 g/kg of body weight of glucose. 5S rRNA
was used as a loading control. Relative expression of miR-7/5S is expressed as a fold change compared to that in control hypothalamus (Fast).
(Right) Initial glycemic levels before and at the end of the STZ treatment (n 4 per group). *, P 0.05 compared with initial glycemia.
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state and an active region of transcription. Using a combination of bioinformatics tools
(Consite, Genomatix, and EDP), we identified several conserved SREBP1 binding sites
(E-box elements) as well as a number of binding motifs for transcription factors
involved in SREBP1 activation (Sp1 and Nfy) within the promoter region of human and
mouse HNRNPK (Fig. 7). Notably, using chromatin immunoprecipitation combined with
massively parallel sequencing (ChIP-seq), an SREBP1 binding site as well as two Sp1
sites and one Nfy site were previously identified in the adjacent active promoter region
of human HNRNPK (17). As it has been reported that SREBP1c is the predominant
isoform of SREBP1 upregulated in response to insulin, we hypothesized that it probably
acts as a transcriptional regulator of HNRNPK and miR-7-1 expression. To analyze
whether SREBP1 modulates HNRNPK expression and, consequently, miR-7 levels at the
transcriptional level, we transfected N2a cells with a vector expressing FLAG-tagged
nuclear SREBP1c (nSREBP1c) and measured HNRNPK and miR-7a-1 expression. The
overexpression of nSREBP1c significantly increased the expression of HNRNPK (Fig. 8A),
the precursor and mature forms of miR-7 (Fig. 8B), as well as SREBP1 and its target gene
encoding fatty acid synthase (FASN) (Fig. 8C and D).
In addition to insulin, liver X receptor (LXR), a master regulator of cholesterol and
lipid homeostasis, is a well-known regulator of SREBP1c expression and its transcrip-
tional activation. To determine the ability of LXR to mimic the effect of insulin and
SREBP1c overexpression on miR-7 and HNRNPK, we treated mouse N2a cells with the
synthetic LXR ligand T0901317 (T090) for 24 h and assessed their expression by
qRT-PCR and Western blotting. LXR activation led to a significant induction of HNRNPK
mRNA (Fig. 8E) and protein (Fig. 8H) and the precursor and mature forms of miR-7 (Fig.
8F) as well as the upregulation of its classic transcriptional targets, including ABCA1 and
SREBP1 (Fig. 8G and H). To evaluate this hypothesis in vivo, we treated mice with an LXR
diet or a control diet for seven consecutive days to further analyze the expression of
miR-7 and HNRNPK in the brain. qRT-PCR experiments showed a significant induction
of the LXR target genes encoding ABCA1 and SREBP1c in the brains of mice fed an LXR
diet compared to a control diet (Fig. 8K). More importantly, the miR-7a-1 precursor and
mature miR-7 (Fig. 8J), together with HNRNPK mRNA and protein (Fig. 8I and L), were
also induced in the brain in response to LXR activation and SREBP1c induction in vivo,
corroborating previous results obtained in mouse neuronal cells. Overall, these results
suggest that SREBP1c could act as a potential transcriptional regulator of HNRNPK and
its intronic miR-7 upon insulin stimulation and LXR activation in the brain.
miR-7 controls the expression of its host gene in an autoregulatory feedback
loop. Prediction analysis algorithms show that miR-7 could potentially regulate impor-
tant members of the LXR pathway, including RXR and ABCA1 (Fig. 3B). In addition, a
recent report demonstrated that miR-7 targets LXR (18). Therefore, we tested this in
our mouse neuronal cell line by overexpressing miR-7 and assessing mRNA and protein
levels. miR-7 significantly decreased the levels of ABCA1 and LXR mRNAs in N2a cells
(Fig. 9A). Moreover, overexpression of miR-7 led to a decrease in the ABCA1 protein
level both under basal conditions and during LXR activation with the synthetic agonist
T090 (Fig. 9B). Based on our results, miR-7 blocks insulin and LXR signaling, two
pathways that induce its expression through SREBP1c transcriptional regulation of
HNRNPK. This led us to investigate whether miR-7 could work in a regulatory negative-
feedback-loop manner to control its own levels by affecting HNRNPK expression. To test
this hypothesis, we transfected N2a cells with a CM and miR-7 and analyzed HNRNPK
mRNA and protein levels. Indeed, miR-7 transfection significantly reduced HNRNPK
mRNA levels compared with those in CM-transfected cells. In another set of experi-
ments, we transfected N2a cells with CM and miR-7, and 48 h before harvesting the
cells, we treated them with T090 for 12 or 24 h. As shown in Fig. 9C, HNRNPK mRNA
levels were reduced after miR-7 overexpression. Treatment with T090 induced HNRNPK
protein expression (Fig. 9D). Notably, overexpression of miR-7 significantly impaired the
induction of HNRNPK at each time point of T090 treatment (Fig. 9D). Overall, these
results indicate that miR-7 plays a role in the LXR signaling pathway and that it works
in a regulatory negative-feedback loop by controlling the levels of its host gene.
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FIG 7 HNRNPK promoter analysis shows conserved SREBP1 binding sites. (A) Schematic diagram of human HNRNPK gene loci showing the localization of miR-7.
The active promoter of the HNRNPK region correlates with CpG islands (green) and enriched H3K4Me3 histone marks. ChIP-assayed transcription factors shown
include SP1, SREBP1, and SREBP2 (highlighted in red). Data were compiled using the UCSC Genome Browser (NCBI36/hg18; http://genome.ucsc.edu). (B)
Sequence alignment of the human and mouse HNRNPK promoters (minus strand) showing the localization of predicted Sp1 (orange, 85% confidence; purple,
90% confidence), E-box (green), and NFY (blue) binding sites found using Consite (http://consite.genereg.net/cgi-bin/consite) and Genomatix (http://www
.genomatix.de). Transcription start sites (TSS) are highlighted in red. Genomic locations for human (NCBI36/hg18) and mouse (NCBI37/mm9) are provided at
the top. scaRNA, small cajal RNAs; snoRNA, small nucleolar RNAs.
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Brain miR-7-1 expression is altered during obesity and Alzheimer’s disease.
Given the regulation of miR-7 expression by insulin and LXR, as well as its ability to
block these two neuroprotective pathways, we could anticipate that overstimulation of
miR-7 during hyperinsulinemic or hypercholesterolemic states associated with obesity
or diabetes could have deleterious effects on the brain. Therefore, we decided to
FIG 8 SREBP1c regulates HNRNPK/miR-7 expression. (A) qRT-PCR analysis of HNRNPK in N2a cells transfected with a vector expressing
nuclear SREBP1c or an empty vector. (B) qRT-PCR analysis of precursor miR-7a-1 and mature miR-7 in N2a cells treated as described above
for panel A. (C) qRT-PCR analysis of fatty acid synthase (FAS) and SREBP1 in N2a cells treated as described above for panel A. Data
represent relative expression and correspond to the means SEM from three independent experiments performed in triplicate. *, P 0.05
compared with the empty vector. (D) Representative Western blot analysis of HNRNPK and FASN in cells treated as described above for
panel A. HSP90 was used as a loading control. (E) qRT-PCR analysis of HNRNPK in N2a cells treated with the vehicle or T0901317 (3 M)
for 24 h. (F) qRT-PCR analysis of precursor miR-7a-1 and mature miR-7 in N2a cells treated as described above for panel E. (G) qRT-PCR
analysis of ABCA1 and SREBP1c in N2a cells treated as described above for panel E. Data are expressed as relative expression levels and
correspond to the means SEM from three independent experiments performed in triplicate. *, P 0.05 (significantly different from cells
treated with the vehicle [control] and normalized to a value of 1). (H) Representative Western blot analysis of HNRNPK and ABCA1 in N2a
cells treated with the vehicle or T0901317 (3 M) for 24 h. HSP90 was used as a loading control. (I) qRT-PCR analysis of HNRNPK in brains
of mice fed the control diet or the LXR diet for 1 week. (J) qRT-PCR analysis of precursor miR-7a-1 and mature miR-7 as described above
for panel I. (K) qRT-PCR analysis of ABCA1 and SREBP1c as described above for panel I. Data represent relative expression levels and
correspond to the means  SEM. *, P 0.05 (significantly different compared with the control diet) (n 3 per group). (L) Representative
Western blot of HNRNPK and ABCA1 in brains from mice treated as described above for panel I.
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analyze the levels of miR-7 in the brains of obese mice and mice fed a high-cholesterol
diet. Our results showed that miR-7 expression is significantly elevated in the brain of
diet-induced obese (DIO) mice compared to those in mice fed a control diet (Fig. 10A).
Similar results were observed in mice fed a high cholesterol diet (Fig. 10B). In addition
to insulin resistance, dysregulation of cholesterol metabolism and the LXR signaling
pathway are associated with an increased risk of AD. Specifically, the expression and
function of ABCA1 and ApoE lipidation are strongly linked to amyloidosis, a key
pathological hallmark leading to the progression AD. As indicated above, miR-7 targets
key genes involved in AD, including the IDE, APP, BACE1, PSEN1, ABCA1, and LXR
genes (Fig. 3). Notably, our results show that overexpression of miR-7 not only down-
regulates LXR and ABCA1 expression (Fig. 9A and B) but also increases the levels of
extracellular A in neuronal cells and impairs the clearance of extracellular A by
microglial cells (Fig. 10C and D). Based on these results, we next decided to compare
miR-7 levels in brain samples from healthy subjects to those in brain samples from AD
patients. We found that the expression of miR-7 is significantly elevated in the cortex
of AD patients compared with that in control healthy human subjects, while the
expression of its target genes encoding IRS-2 and IDE is downregulated in AD brains
(Fig. 10E and F). These data, together with our above-described in vitro results, support
the hypothesis that miR-7 acts as a dual negative regulator of insulin and LXR actions
in the brain and, potentially, A metabolism during the progression of AD. Therefore,
FIG 9 miR-7 targets the LXR pathway and controls the expression of its host gene encoding HNRNPK. (A) qRT-PCR
analysis of ABCA1 and LXR mRNA expression levels in N2a cells transfected with a control mimic (CM) or an
miR-7-5p mimic (miR-7). Data are expressed as relative expression levels and correspond to the means SEM from
three independent experiments performed in triplicate. *, P 0.05 (significantly different from cells transfected
with the CM [normalized to a value of 1]). (B) Representative Western blot analysis of ABCA1 in N2a cells transfected
with the CM or miR-7 and treated with the vehicle or with T0901317 for 24 h. (C) qRT-PCR analysis of HNRNPK
mRNA expression levels in N2a cells transfected with a CM or an miR-7-5p mimic (miR-7). Data are expressed as
relative expression levels and correspond to the means  SEM from 3 independent experiments performed in
triplicate. *, P 0.05 (significantly different from cells transfected with CM [normalized to a value of 1]). (D, left)
Representative Western blot of HNRNPK in N2a cells transfected with the CM or miR-7-5p for 48 h and treated with
the vehicle or T0901317 (3 M) for 12 and 24 h. HSP90 was used as a loading control. (Right) Relative HNRNPK/
HSP90 levels from three independent experiments. *, P 0.05 (significantly different from cells transfected with CM
at each time point of T090 treatment); #, P 0.01 (significantly different from cells transfected with the CM at time
zero of T090 treatment).
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miR-7 could represent a potential therapeutic target for the treatment of insulin
resistance and neurodegeneration-associated diseases such as AD.
DISCUSSION
Extensive preclinical and clinical evidence supports a pathophysiological connection
between Alzheimer’s disease (AD) and diabetes (1, 19, 20). Due to the strong correlation
FIG 10 miR-7 levels are elevated in brains of obese mice (hypothalamus) and in Alzheimer’s disease patients. (A) qRT-PCR analysis
of pre-miR-7a-1 and mature miR-7-5p in the hypothalamus of mice fed a chow diet (CD) or DIO mice (n 5 per group). *, P 0.05
compared with CD mice. (B) qRT-PCR analysis of pre-miR-7a-1 and mature miR-7-5p in the hypothalamus of mice fed a chow diet
(CD) or a HFD (n 5 per group). (C and D, top) Representative Western blot analysis measuring levels of A in the media of
N2a-APPsw (C) and BV-2 (D) cells after transfection with a CM or miR-7. (Bottom) Relative A levels corresponding to the means 
SEM from two independent experiments performed in triplicate. *, P 0.05 (significantly different from cells transfected with the
CM [normalized to a value of 1]). (E) qRT-PCR analysis of mature miR-7-5p in human cortex and cerebellum from human AD
patients and matching healthy human subjects (n 5 per group). *, P 0.05 compared with control healthy subjects. (F) qRT-PCR
analysis of IRS-2 and IDE in cortex from human AD patients and matching healthy human subjects (n 5 per group). *, P 0.05
compared with control healthy subjects.
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between brain insulin resistance (IR) and the pathogenesis of AD, AD has been
proposed as “type 3” diabetes (21, 22). Yet the molecular mechanism underlying this
relation is still elusive. MicroRNAs have been shown to play a major role in the
regulation of metabolism, primarily in peripheral tissues (23). The brain expresses more
distinct and the largest number of miRNAs than any other tissue in vertebrates (24), and
they are involved in a plethora of physiological functions, in neuronal differentiation,
and in pathological states, such as the development of brain tumors and neurodegen-
eration. Here, we describe a novel role of miR-7, a microRNA enriched in the brain, in
regulating important insulin and LXR signaling components, two main neuroprotective
pathways that can influence IR as well as A metabolism, thus representing a novel
common regulator linking brain insulin resistance and AD at the posttranscriptional
level. Among the possible mechanisms underlying the connection between both
diseases, IR and amyloidosis are prominent and closely related (25). Our data show that
miR-7 regulates the expression of not only INSR and IRS-2, inhibiting the downstream
insulin signaling cascade in neuronal cells, but also IDE, LXR, and ABCA1, involved in
A metabolism. The LXR signaling pathway plays an important role in A plaque
biogenesis. Loss of LXRs increases A plaque burden in the APP/PS1 mouse (26–29).
ABCA1, one of the most studied transcriptional targets of LXR, affects the lipidation
status of ApoE in the brain, which in turn may facilitate the proteolytic degradation
of A (30). Indeed, we and others have shown that microRNAs that affect ABCA1,
such as miR-33 and miR-106, play a key role in AD pathology (11, 31). Therefore, it
is possible that increased A levels in neuronal cells and impairment of uptake by
microglial cells after miR-7 overexpression could be mediated through the post-
transcriptional regulation of this pathway. Nevertheless, several remarkable char-
acteristics distinguish miR-7 as a unique miRNA in the context of the possible
underlying molecular coregulation of brain IR and AD. miR-7 is a highly abundant
microRNA in the brain, and intriguingly, it targets key genes involved in IR and AD.
In this regard, it is generally accepted that miRNAs with biological significance
usually target entire pathways rather than a single mRNA involved in a biological
function. Another important miR-7 target is IDE, a strong candidate for involvement
in late-onset AD (32) which represents a common molecular link between IR and
AD. Indeed, IDE expression, which has been shown to influence A levels in vitro
and in vivo (33), is also impaired in brains from AD patients and in Tg2576
transgenic mice and correlates with the accumulation of A during the progression
of the disease. In this line, it is possible that our findings of elevated miR-7 levels
in the brains of AD patients compared with those in healthy subjects could account
for this effect as well as for the reduced levels of its target IRS-2 mRNA during the
progression of AD (22). Moreover, we also found that levels of miR-7 are altered in
brains of obese mice fed a high-cholesterol diet and of DIO mice; this correlates
with increased brain insulin signaling previously described in this animal model as
well as in ob/ob mice and in monkeys with long-standing diet-induced type 2
diabetes mellitus (T2DM) (34). Several studies suggest that the brain is initially
hyperinsulinized in insulin-resistant states of obesity, metabolic syndrome, and
T2DM and that with the development and progression of AD pathology, the brain
may secondarily become insulin resistant. In this context, we found that miR-7 is
induced by insulin and LXR, both in vitro and in vivo, and this effect is abolished
when systemic insulin levels are compromised in an STZ-induced model of type 1
diabetes mellitus (T1DM).
Our data indicate that miR-7-1a, encoded in intron 17 of the mouse HNRNPK gene,
is cotranscribed with the host gene, which is a common mechanism for intronic miRNAs
(9, 35, 36). Although we cannot exclude additional regulation, the HNRNPK promoter
contains several conserved E-box sequence motifs and consensus sequences for the
well-known SREBP1 coregulator NFY and the insulin transducer transcription factor SP1.
These results, together with the data showing an increase in miR-7 with the host gene
upon overexpression of an active SREBP1c form in neuronal cells, suggest a possible
SREBP1c-mediated transcriptional mechanism of HNRNPK/miR-7 through insulin/LXR
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pathways. Further analyses are necessary to explore the potential direct transcriptional
activation of HNRNPK/miR-7 by LXR. In this regard, activation of LXR drives cholesterol
efflux through ABCA1/ABCG1 transcriptional regulation. This effect could lead to
cellular cholesterol depletion and indirect activation of SREBP2. Indeed, data compiled
using the UCSC Genome Browser shows ChIP-assayed binding for this transcription
factor, which suggests a possibly more complex scenario for the regulation of HNRNPK/
miR-7. After LXR agonist or insulin stimulation, the levels of miR-7-1 are increased, and
it inhibits a number of insulin and LXR pathway components, including INSR, IRS-2, AKT,
LXR, RXR, and possibly other potential downstream targets, such as the SREBP1
coregulators NFY and SP1 (Fig. 11). This negative autoregulatory feedback loop was
later corroborated when LXR-dependent stimulation of HNRNPK, which lacks miR-7’s
binding sites in its 3= UTR, was inhibited by miR-7 overexpression in N2a cells. Multiple
examples in the literature have shown that intronic miRNAs involved in autoregulatory
mechanisms fine-tune metabolic pathways by directly or indirectly regulating their host
gene. Negative-feedback regulation by direct targeting of host genes has been de-
scribed for miR-126 (37) and miR-128b (38), among others. On the other hand, studies
indicate that miR-33a and -b, encoded by Srebp2 and Srebp1, respectively, are cotran-
scribed with their host genes and regulate cellular cholesterol levels and insulin
signaling, which in turn dictate Srebp2 and Srebp1 expression and activity, thus con-
trolling their own expression (23). In the context of our study, it is conceivable that
overproduction of miR-7 during states of metabolic dysregulation, as in hyperinsulin-
ized brains during obesity, metabolic syndrome, and T2DM (34), could ameliorate the
neuroprotective actions of insulin and LXR in the brain, promoting later IR and
amyloidosis, thus representing a molecular link between insulin resistance and AD at
the posttranscriptional level. Therefore, our work depicts miR-7 as a potential thera-
peutic target for the treatment of insulin resistance and associated neurodegenerative
diseases such as AD.
FIG 11 Schematic showing the proposed mechanism of action and regulation of HNRNPK/miR-7. Upon
insulin signaling or LXR activation, induced SREBP1c can form a transcriptional complex with Sp1 and
NFY and binds to sterol regulatory elements (SREs) in the promoter region of HNRNPK, leading to its
transcriptional activation. miR-7-1, encoded in intron 16 of the human HNRNPK gene, is cotranscribed
with the host gene and targets a number of insulin signaling and LXR pathway components, regulating
its own expression in a negative-feedback loop. By affecting both LXR and insulin signaling genes, altered
levels of miR-7 during states of metabolic dysregulation could ameliorate neuroprotective actions of
insulin and LXR in the brain, thus representing a possible molecular link between insulin resistance and
AD at the posttranscriptional level.
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MATERIALS AND METHODS
All chemicals were obtained from Sigma unless otherwise noted. The pcDNA3.1-2FLAG-SREBP1c
vector and the empty control vector were obtained from Addgene.
Cell culture and treatments. The mouse neuroblastoma N2a cell line and BV-2 microglial cells,
obtained from the American Type Culture Collection, were maintained in Dulbecco’s modified Eagle
medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2% penicillin-streptomycin, and
L-glutamine in 10-cm2 dishes at 37°C with 5% CO2. N2a cells are a fast-growing neuroblastoma cell line
from mouse that has been widely used to study neurotoxicity, metabolism, miRNAs, and Alzheimer’s
disease (11). For some experiments, cells were treated with 100 nM insulin at different time points or
T0901317 at 3 M for 12 and 24 h.
Bioinformatic analysis of miRNA target genes. Predicted target genes for miR-7 were identified
using TargetScan 6.2. Putative targets were uploaded into the Panther v8.0 gene classification system
(http://www.pantherdb.org) to analyze pathway enrichment. Genes within the significantly enriched
pathway were uploaded to String v9.05 (http://string-db.org), and String interactions and GeneMania
software were used to represent networks of predicted targets involved in Alzheimer’s disease (https://
genemania.org).
Transfection of miRNA mimics and miRNA inhibitors. Cells (70% confluence) were transfected
with 40 nM the miRIDIAN miRNA mimic (miR-7-5p) or with 60 nM the miRIDIAN miRNA inhibitor
(Inh-miR-7-5p) (Dharmacon) by utilizing Lipofectamine RNAiMax (Invitrogen) and studied 48 h later. In all
experiments, an equal concentration of a nontargeting control mimic (CM) sequence or an inhibitor
negative control sequence was used as a control for non-sequence-specific effects in miRNA experi-
ments. Verification of miR-7 overexpression and knockdown was performed using quantitative PCR
(qPCR) as described below.
3=-UTR luciferase reporter assays. cDNA fragments corresponding to the 3= UTRs of the human
INSR, IRS-2, and IDE genes were amplified by reverse transcription-PCR from genomic DNA with XhoI and
NotI linkers. The PCR products were directionally cloned downstream of the Renilla luciferase open
reading frame in the psiCHECK2 vector (Promega), which also contains a constitutively expressed firefly
luciferase gene, which is used to normalize transfections. Site-directed mutations in the seed region of
predicted miR-7 sites within the 3= UTRs were generated using a QuikChange multisite-directed mu-
tagenesis kit (Agilent) according to the manufacturer’s protocol. All constructs were confirmed by
sequencing. COS-7 cells were plated into 12-well plates and cotransfected with 1 g of the indicated
3=-UTR luciferase reporter vectors and the miR-7-5p mimic or negative-control mimic (Dharmacon), using
Lipofectamine RNAiMax (Invitrogen). Luciferase activity was measured using the Dual-Glo luciferase assay
system (Promega). Renilla luciferase activity was normalized to the corresponding firefly luciferase activity
and plotted as a percentage of the control (CM). Experiments were performed in triplicate at least three
times.
RNA isolation and quantitative real-time PCR. Total RNA from cells and mouse tissues was isolated
using TRIzol reagent (Invitrogen) according to the manufacturer’s protocol. For mRNA quantification,
1 g of total RNA was reverse transcribed to cDNA using iScript RT supermix (Bio-Rad), according to the
manufacturer’s protocol. Quantitative real-time PCR was performed in triplicate using iQ SYBR green
supermix (Bio-Rad) on a real-time detection system (Eppendorf). The mRNA level was normalized to the
level of 18S rRNA as a housekeeping gene. Primer sequences are available upon request. For miRNA
quantification, total RNA was reverse transcribed using the miScript II RT kit (Qiagen). Primers specific for
mouse precursor miRNAs (pre-miR-7) and mature miR-7-5p (Qiagen) were used, and values were
normalized to the levels of SNORD68 mRNA, as a housekeeping gene.
Western blot analysis. Cells were lysed in ice-cold buffer containing 50 mM Tris-HCl (pH 7.4), 0.1 mM
EDTA, 0.1 mM EGTA, 1% NP-40, 0.1% sodium deoxycholate, 0.1% SDS, 100 mM NaCl, 10 mM NaF, 1 mM
sodium pyrophosphate, 1 mM sodium orthovanadate, 1 mM Pefabloc, and 2 mg/ml protease inhibitor
cocktail (Roche Diagnostics Corp.). Protein concentrations were determined using the DC protein assay
kit (Bio-Rad Laboratories). Cell lysates containing 12.5 to 25 g of protein were analyzed by SDS-PAGE
and immunoblotting. Primary antibodies used included antibodies to HNRNPK (catalog number 4675;
Cell Signaling), INSR (catalog number NBP1-19192), IDE (catalog number ab32216; Cell Signaling), IRS-1
(catalog number NB-10082001; Novus Biologicals), IRS-2 (catalog number A301-433A; Bethyl), IGF1R
(catalog number 3027S; Cell Signaling), GSK3 (catalog number 9315S; Cell Signaling), p-GSK3 (catalog
number 9322S; Cell Signaling), AKT (catalog number 9272; Cell Signaling), p-AKT (catalog number 9277;
Cell Signaling), ABCA1 (catalog number ab18180; Abcam), anti-A antibody (catalog number 82E1; IBL
International), FASN (catalog number ab22759; Abcam), and heat shock protein 90 (HSP90) (catalog
number 610419; BD Bioscience). Secondary antibodies were fluorescence-labeled antibodies, and bands
were visualized using the Odyssey infrared imaging system (Li-Cor Biotechnology). Densitometry analysis
of the Western blots was carried out by using ImageJ software from the NIH (http://rsbweb.nih.gov/ij/).
Northern blot analysis. Total RNA (10g) of mouse tissues was resolved in a 15% polyacrylamide gel
and blotted onto a Hybond-N nylon membrane (Amersham Biosciences). miRCURY LNA detection probe
DNA oligonucleotides for hsa-miR-7-5p were purchased from Exiqon. The oligonucleotide sequence 5=-ACA
ACAAAATCACTAGTCTTCC-3=, which is complementary to thematuremiRNA, was end labeled with [-32P]ATP
and T4 polynucleotide kinase (New England Biolabs) to generate high-specific-activity probes. The oligonu-
cleotide sequence for 5S rRNA was 5=-CAGGCCCGACCCTGCTTAGCTTCCGAGATCAGACGAGAT-3=. Hybridiza-
tion was carried out according to the Express Hyb (Bio-Rad) protocol. Probes were washed twice for 10 min
at 25°C in 4 SSC (1 SSC is 0.15 M NaCl plus 0.015 M sodium citrate)–0.5% SDS.
Mouse studies. Eight-week-old male C57BL/6 mice were purchased from Jackson Laboratories (Bar
Harbor, ME) and kept under constant temperature and humidity in a 12-h controlled dark/light cycle. All
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animal experiments were approved by the Institutional Animal Care and Use Committee of the Yale
University School of Medicine. For high-fat diet (HFD) studies, 8-week-old male mice (n 5 per group)
were placed on a chow diet or a HFD (Western diet, 1.25% cholesterol, catalog number D12103C;
Research Diets) for 12 weeks. For DIO studies, 8-week-old male wild-type (WT) mice (n 5 per group)
were fed a chow diet or a 60% fat diet (catalog number D12492; Research Diets) for 10 weeks. For the
type 1 diabetes model, 8-week-old male WT mice (n 4 per group) were treated with a daily intraper-
itoneal (i.p.) injection (200 g/g of body weight) of STZ for seven consecutive days. Glucose levels were
monitored using a OneTouch Ultra glucometer (LifeScan Canada Ltd.). For some experiments, 8-week-old
male WT mice (n 4 per group) were fasted for 16 h and injected i.p. with glucose (2 g/kg of body
weight). Brain tissues were dissected 0, 1, and 3 h after the injection. For LXR activation in vivo,
8-week-old male WT mice (n 3 per group) were fed a control standard diet (15 kcal% fat, catalog
number D11112201; Research Diets) or an LXR-enriched diet (standard diet plus 3,212.5 mg of
T0901317/kg diet, catalog number D16113001; Research Diets) for seven consecutive days. After the
treatments or diet periods, mice were sacrificed, and brain tissue samples were dissected and stored at
80°C until processing for protein or gene expression analysis.
A secretion assay. N2a-APPsw cells were plated at a density of 2.5 105 cells/well in a 12-well
plate 1 day before transfection. N2a-APPsw cells were transfected with synthetic miR-7 or the negative
control (Insight Genomics) using Lipofectamine RNAiMax (Invitrogen). Forty-eight hours after transfec-
tion, media were changed to Opti-MEM-I (Invitrogen). Six hours after the medium change, the cells and
media were collected for Western blot analysis. For A detection, the same volumes of media were run
on a 16.5% Tris-Tricine gel (Bio-Rad) as previously described (39). All experiments were performed in
triplicate and repeated independently twice.
A clearance assay. BV2 cells were plated at a density of 5 105 cells/well in a 12-well plate. BV2
cells were transfected with miR-7 or a negative control (Insight Genomics) using Lipofectamine RNAiMax
(Invitrogen). Twenty-four hours after transfection, cells were incubated in fresh DMEM–N2–1 mM sodium
pyruvate medium containing 40 nM synthetic A40 for 24 h, and the remaining A levels were then
analyzed by Western blotting using culture medium. A levels were normalized by total protein levels.
All experiments were performed in triplicate and repeated independently twice.
Human brain samples. Postmortem human brains (area 9) without any severe neurological and
psychological disorders and brains with severe dementia of the Alzheimer type were obtained from
autopsies performed at the University of Kentucky (Peter T. Nelson). The postmortem interval (PMI) range
was between 1 and 4 h. The different cases are described in Table 1. The experiments were undertaken
with the approval of the Ethics Committee of the University of Kentucky.
Statistical analysis. In vitro experiments were routinely repeated at least three times unless
otherwise noted. Data are expressed as means  standard errors of the means (SEM) unless otherwise
indicated. Statistical differences were measured using unpaired two-sided Student’s t test, one-way
analysis of variance (ANOVA) with Bonferroni correction for multiple comparisons, or a log rank test when
appropriate. Normality was checked using the Kolmogorov-Smirnov test. A nonparametric test (Mann-
Whitney) was used when data did not pass the normality test. A P value of 0.05 was considered
statistically significant. Data analysis was performed using Prism software version 7 (GraphPad, San
Diego, CA).
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